Effect of amiodarone in postoperative atrial fibrillation after coronary artery bypass surgery

Effect of prophylactic amiodarone in the prevention of postoperative atrial fibrillation after coronary artery bypass surgery in Mazandaran Heart Center

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014090813156N7

Enrollment

150

Registered

2014-12-30

Start date

2014-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CAD in CABG. Mechanical complication of coronary artery bypass and valve grafts

Interventions

Intervention 1: Control group: in this group use placebo (structured by normal saline serum) that similiar to Amiodarone Ampules and tablets. according to this research, anesthesia and patient do not

two times infuse placebo and after that in ICU ward infuse drip in 24 hrs, then oral placebo are fed until discharge. Preoperative and Postoperative atrial size and ejection fraction measured.

Placebo

Treatment - Drugs

Control group: in this group use placebo (structured by normal saline serum) that similiar to Amiodarone Ampules and tablets. according to this research, anesthesia and patient do not inform about inf

two times infuse placebo and after that in ICU ward infuse drip in 24 hrs, then oral placebo are fed until discharge. Preoperative and Postoperative atrial size and ejection fraction measured

Amiodarone: Amiodarone vial 2 vials 2 ml ampoules equivalent to 300 mg amiodarone, the surgical incision during a time period of 20 minutes through a central venous catheter, and the next dose as DrIp

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criterion: preoperative sinus rhythm. Exclusion criteria: allergy to amiodarone or use of amiodarone in the last 6 months; history of toxicity with amiodarone, anti-arrhythmic therapy before surgery; thyroid disease; aspartate aminotransferase or alanine aminotransferase concentration 4 times higher than normal; pregnant patients, a lower rate 50; heart failure; AV block and surgical history of lung disease and hepatitis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The incidence of atrial fibrillation. Timepoint: During hospitalization. Method of measurement: Monitoring.	—

Secondary

Measure	Time frame
Hospitalization time. Timepoint: During hospitalization. Method of measurement: Monitoring and documentation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKaveh Jafari

Mazandaran University of Medial Sciences

kavehjafari@yahoo.com+98 911 780 7886

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026